Blom E J, Klein-Nulend J, Wolke J G C, Kurashina K, van Waas M A J, Burger E H
Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam, The Netherlands.
Biomaterials. 2002 Feb;23(4):1261-8. doi: 10.1016/s0142-9612(01)00246-0.
The osteoconductive properties of calcium phosphate cements (CPCs) may be improved by the addition of growth factors, such as recombinant human transforming growth factor-beta1 (rhTGF-beta1). Previously we have shown that rhTGF-beta1 was released from cement enriched with rhTGF-beta1 and subsequently stimulated the differentiation of pre-osteoblastic cells from adult rat long bones. It is unknown whether the addition of rhTGF-beta1 changes the material properties of this alpha-tricalcium-phosphate (alpha-TCP)/tetracalcium-phosphate-monoxide (TeCP)/dicalcium-phosphate-dihydrate (DCPD) cement, and what the characteristics of the release of rhTGF-beta1 from this CPC are. Therefore, in the present study we determined the release of rhTGF-beta1 from cement pellets in vitro. The possible intervening effects of the CPC modification for intermixing rhTGF-beta1 on physicochemical properties were studied by assessing the compressive strength and setting time, as well as crystallinity, calcium to phosphorus ratio, porosity and microscopic structure. Most of the previously incorporated rhTGF-beta1 in the cement pellets was released within the first 48 h. For all concentrations of rhTGF-beta1 intermixed (100 ng-2.5 mg/g CPC), approximately 0.5% of the amount of rhTGF-beta1 incorporated initially was released in the first 2 h, increasing to 1.0% after 48 h. The release of rhTGF-beta1 continued hereafter at a rate of about 0.1% up to 1 week, after which no additional release was found. The initial setting time, nor the final setting time was changed in control cement without rhTGF-beta1 (standard CPC) or in cement modified for rhTGF-beta1 (modified CPC) at 20 degrees C and 37 degrees C. Setting times were more than six times decreased at 37 degrees C compared to 20 degrees C. The compressive strength was initially low for both standard CPC and modified CPC, after which it increased between 24 h and 8 weeks. The compressive strength for the modified CPC was significantly higher compared with standard at 1, 2, and 8 weeks after mixing. X-ray diffraction revealed that both standard and modified CPC changed similarly from the original components into crystalline apatite. The calcium to phosphorus ratio as determined by an electron microprobe did not differ at all time points measured for standard CPC and modified CPC. In both standard CPC and modified CPC the separated particles became connected by crystals, forming a structure in which the particles could hardly be recognised in a densifying matrix with some small pores. The present study shows that the calcium phosphate cement is not severely changed by modification for the addition of rhTGF-beta1. The addition of rhTGF-beta1 in CPC enhances the biologic response as shown in our previous study and did not interfere with the aimed physical and chemical properties as shown in this study. We conclude that the addition of rhTGF-beta1 enlarges the potential of the CPC in bone replacement therapy.
通过添加生长因子,如重组人转化生长因子-β1(rhTGF-β1),磷酸钙骨水泥(CPCs)的骨传导特性可能会得到改善。此前我们已经表明,rhTGF-β1从富含rhTGF-β1的骨水泥中释放出来,并随后刺激成年大鼠长骨中前成骨细胞的分化。目前尚不清楚添加rhTGF-β1是否会改变这种α-磷酸三钙(α-TCP)/磷酸四钙-一氧化碳(TeCP)/二水磷酸二钙(DCPD)骨水泥的材料特性,以及rhTGF-β1从这种CPC中的释放特性是什么。因此,在本研究中,我们测定了rhTGF-β1从骨水泥微丸中的体外释放情况。通过评估抗压强度、凝固时间以及结晶度、钙磷比、孔隙率和微观结构,研究了用于混合rhTGF-β1的CPC改性对物理化学性质可能产生的干预作用。骨水泥微丸中先前掺入的大部分rhTGF-β1在最初的48小时内释放。对于所有混合浓度的rhTGF-β1(100 ng - 2.5 mg/g CPC),最初掺入的rhTGF-β1量的约0.5%在最初2小时内释放,48小时后增加到1.0%。此后,rhTGF-β1以约0.1%的速率持续释放直至1周,之后未发现额外释放。在20℃和37℃下,不含rhTGF-β1的对照骨水泥(标准CPC)或经rhTGF-β1改性的骨水泥(改性CPC)的初凝时间和终凝时间均未改变。与20℃相比,37℃下的凝固时间缩短了六倍多。标准CPC和改性CPC的抗压强度最初都较低,之后在24小时至8周之间增加。混合后1、2和8周时,改性CPC的抗压强度明显高于标准CPC。X射线衍射显示,标准CPC和改性CPC从原始成分向结晶磷灰石的变化相似。通过电子微探针测定的钙磷比在标准CPC和改性CPC测量的所有时间点均无差异。在标准CPC和改性CPC中,分离的颗粒都通过晶体连接,形成了一种结构,在致密化的基质中有一些小孔,颗粒几乎难以辨认。本研究表明,添加rhTGF-β1对磷酸钙骨水泥的改性影响不大。如我们先前的研究所表明,在CPC中添加rhTGF-β1增强了生物学反应,并且如本研究所表明,并未干扰目标物理和化学性质。我们得出结论,添加rhTGF-β1扩大了CPC在骨替代治疗中的潜力。